Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 148 participants.
Also called NCT02081599
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 148 participants
- Sponsor
- Registry
-
NCT02081599
-
- Other papers using this trial's data
- Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02081599. Randomized; quadruple masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2016-01 (actual). Results posted on 2017-01-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Teneli (Teneligliptin)
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Insulin
- Lead sponsor
- Tanabe Pharma Corporation
Record details
- Record id
cardio:ct-nct02081599- Content hash
9b55ecf83c4bd771211a6331a9b3e9a168428338d7e132e1d9036c7991a23254